Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis

被引:138
|
作者
Richeldi, Luca [1 ,2 ]
Ryerson, Christopher J. [3 ]
Lee, Joyce S. [2 ]
Wolters, Paul J. [2 ]
Koth, Laura L. [2 ]
Ley, Brett [2 ,4 ]
Elicker, Brett M.
Jones, Kirk D. [5 ]
King, Talmadge E., Jr. [2 ]
Ryu, Jay H. [6 ]
Collard, Harold R. [2 ]
机构
[1] Univ Modena & Reggio Emilia, Ctr Rare Lung Dis, I-41100 Modena, Italy
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[4] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA
[6] Mayo Clin, Dept Pulm & Crit Care Med, Rochester, MN USA
关键词
PLACEBO-CONTROLLED TRIAL; PIRFENIDONE; STANDARDIZATION; BOSENTAN;
D O I
10.1136/thoraxjnl-2011-201184
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Decline in forced vital capacity (FVC) over time reliably predicts mortality in patients with idiopathic pulmonary fibrosis. The use of this measure in clinical practice is recommended by current evidence-based guidelines. It is unknown if the method of calculating decline in FVC (relative vs absolute change) impacts its frequency or its ability to predict mortality. Methods Patients with idiopathic pulmonary fibrosis from two prospective cohorts were included if they had a baseline and 12-month follow-up FVC. A >= 10% decline in FVC from baseline was calculated in two ways: a relative decline of 10% (eg, from 60% predicted to 54% predicted) and an absolute decline of 10% (eg, from 60% predicted to 50% predicted). The frequency of a >= 10% decline in FVC and its ability to predict 2-year transplant-free survival were compared between these two methods. Declines in FVC of >= 5% and >= 15% were similarly compared. Analyses were performed unadjusted and adjusted for age, gender, use of oxygen, baseline FVC and baseline diffusion capacity for carbon monoxide. Results The frequency of any given FVC decline was significantly greater using the relative change in FVC method. For >= 10% decline, both methods predicted 2-year transplant-free survival with similar accuracy, and remained significant predictors after adjusting for baseline characteristics. The absolute change method appeared more predictive for >= 5% decline. Conclusions Using the relative change in FVC maximises the chance of identifying a >= 10% decline in FVC without sacrificing prognostic accuracy. This may not hold true for >= 5% decline in FVC. These findings have important implications for clinical practice and the design of clinical trials.
引用
收藏
页码:407 / 411
页数:5
相关论文
共 50 条
  • [1] Relative Versus Absolute Decline in Forced Vital Capacity in Progressive Pulmonary Fibrosis
    Castro, Horacio Matias
    Furcada, Joaquin Maritano
    Enghelmayer, Juan Ignacio
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (12): : 843 - 844
  • [2] Reference values for forced vital capacity in idiopathic pulmonary fibrosis
    Pereira, Carlos A. C.
    [J]. RESPIRATORY MEDICINE, 2017, 125 : 102 - 102
  • [3] Change In Forced Vital Capacity And Clinical Outcomes In Newly Diagnosed Idiopathic Pulmonary Fibrosis Patients
    Nathan, S. D.
    Reichmann, W. M.
    Macaulay, D.
    Yu, Y. F.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [4] Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis
    Pesonen, Ida
    Gao, Jing
    Kalafatis, Dimitrios
    Carlson, Lisa
    Myllarniemi, Marjukka
    Ferrara, Giovanni
    Skold, Magnus
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [5] Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis
    Behr, J.
    Bonella, F.
    Bonnet, R.
    Glaeser, S.
    Grohe, C.
    Guenther, A.
    Koschel, D.
    Kreuter, M.
    Kirsten, D.
    Kroegel, C.
    Markart, P.
    Mueller-Quernheim, J.
    Neurohr, C.
    Pfeifer, M.
    Prasse, A.
    Schoenfeld, N.
    Schreiber, J.
    Wirtz, H.
    Witt, C.
    Costabel, U.
    [J]. PNEUMOLOGIE, 2015, 69 (08): : 455 - 458
  • [6] Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity
    Bermudo, Guadalupe
    Suarez-Cuartin, Guillermo
    Rivera-Ortega, Pilar
    Rodriguez-Portal, Jose Antonio
    Sauleda, Jaume
    Nunez, Belen
    Castillo, Diego
    Aburto, Myriam
    Portillo, Karina
    Balcells, Eva
    Badenes-Bonet, Diana
    Valenzuela, Claudia
    Fernandez-Fabrellas, Estrella
    Gonzalez-Budino, Teresa
    Cano, Esteban
    Acosta, Orlando
    Leiro-Fernandez, Virginia
    Romero, Ana
    Planas-Cerezales, Lurdes
    Villar, Ana
    Moreno, Amalia
    Laporta, Rosalia
    Vicens-Zygmunt, Vanesa
    Shull, Jessica
    Franquet, Tomas
    Luburich, Patricio
    Molina-Molina, Maria
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (02): : 135 - 141
  • [7] The Effect Of Bronchodilators On Forced Vital Capacity In Patients With Idiopathic Pulmonary Fibrosis
    Assayag, D.
    Vittinghoff, E.
    Ryerson, C. J.
    Cocconcelli, E.
    Tonelli, R.
    Elicker, B.
    Golden, J.
    Jones, K. D.
    King, T. E.
    Koth, L. L.
    Lee, J. S.
    Ley, B.
    Wolters, P. J.
    Collard, H. R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [8] Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis
    Reichmann, William M.
    Yu, Yanni F.
    Macaulay, Dendy
    Wu, Eric Q.
    Nathan, Steven D.
    [J]. BMC PULMONARY MEDICINE, 2015, 15
  • [9] Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis
    William M. Reichmann
    Yanni F. Yu
    Dendy Macaulay
    Eric Q. Wu
    Steven D. Nathan
    [J]. BMC Pulmonary Medicine, 15
  • [10] Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
    Santermans, Eva
    Ford, Paul
    Kreuter, Michael
    Verbruggen, Nadia
    Meyvisch, Paul
    Wuyts, Wim A.
    Brown, Kevin K.
    Lederer, David J.
    Byrne, Adam J.
    Molyneaux, Philip L.
    Sivananthan, Arunon
    Moor, Catharina C.
    Maher, Toby M.
    Wijsenbeek, Marlies
    [J]. ADVANCES IN THERAPY, 2019, 36 (11) : 3059 - 3070